AAAAAA
Results: 1-25/46
Authors:
Baselga, J
Citation: J. Baselga, Is circulating HER-2 more than just a tumor marker?, CLIN CANC R, 7(9), 2001, pp. 2605-2607
Authors:
Peinado, C
Salvador, EF
Baselga, J
Catalina, F
Citation: C. Peinado et al., Fluorescent probes for monitoring the UV curing of acrylic adhesives, 1 - FTIR and fluorescence in real time, MACRO CH P, 202(9), 2001, pp. 1924-1934
Authors:
Cabanelas, JC
Serrano, B
Gonzalez-Benito, J
Bravo, J
Baselga, J
Citation: Jc. Cabanelas et al., Morphology of epoxy/polyorganosiloxane reactive blends, MACRO RAPID, 22(9), 2001, pp. 694-699
Authors:
Baselga, J
Citation: J. Baselga, The EGFR as a target for anticancer therapy - focus on cetuximab, EUR J CANC, 37, 2001, pp. S16-S22
Authors:
Bellmunt, J
de Wit, R
Albanell, J
Baselga, J
Citation: J. Bellmunt et al., A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer, EUR J CANC, 37(17), 2001, pp. 2212-2215
Authors:
Baselga, J
Citation: J. Baselga, Clinical trials of Herceptin (R) (trastuzumab), EUR J CANC, 37, 2001, pp. S18-S24
Authors:
Baselga, J
Albanell, J
Citation: J. Baselga et J. Albanell, Mechanism of action of anti-HER2 monoclonal antibodies, ANN ONCOL, 12, 2001, pp. 35-41
Authors:
Baselga, J
Citation: J. Baselga, Phase I and II clinical trials of trastuzumab, ANN ONCOL, 12, 2001, pp. 49-55
Authors:
Baselga, J
Citation: J. Baselga, Targeting the epidermal growth factor receptor: A clinical reality, J CL ONCOL, 19(18), 2001, pp. 41S-44S
Authors:
Baselga, J
Albanell, J
Molina, MA
Arribas, J
Citation: J. Baselga et al., Mechanism of action of trastuzumab and scientific update, SEMIN ONCOL, 28(5), 2001, pp. 4-11
Authors:
Albanell, J
Rojo, F
Baselga, J
Citation: J. Albanell et al., Pharmacodynamic studies with the epidermal growth factor receptor tyrosinekinase inhibitor ZD1839, SEMIN ONCOL, 28(5), 2001, pp. 56-66
Authors:
Baselga, J
Citation: J. Baselga, Herceptin((R)) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials, ONCOL-BASEL, 61, 2001, pp. 14-21
Authors:
Slamon, DJ
Leyland-Jones, B
Shak, S
Fuchs, H
Paton, V
Bajamonde, A
Fleming, T
Eiermann, W
Wolter, J
Pegram, M
Baselga, J
Norton, L
Citation: Dj. Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2., N ENG J MED, 344(11), 2001, pp. 783-792
Authors:
Mikes, F
Gonzalez-Benito, J
Baselga, J
Citation: F. Mikes et al., Monitoring of curing process by fluorescence technique. Fluorescence probeand label based on 5-dimethylaminonaphthalene-1-sulfonamide derivatives (DNS), J MACR S PH, B40(3-4), 2001, pp. 405-428
Authors:
Gonzalez-Benito, J
Mikes, F
Bravo, J
Aznar, AJ
Baselga, J
Citation: J. Gonzalez-benito et al., Fluorescence monitoring of curing process and water accessibility at glassfiber/epoxy interphase on composite materials, J MACR S PH, B40(3-4), 2001, pp. 429-441
Authors:
Granados, EG
Gonzalez-Benito, J
Baselga, J
Dibbern-Brunelli, D
Atvars, TDZ
Esteban, I
Pierola, IF
Citation: Eg. Granados et al., Phase-separated polymer blends: Complementary studies between scanning electron microscopy, epifluorescence microscopy, and fluorescence microspectroscopy, J APPL POLY, 80(7), 2001, pp. 949-955
Authors:
Carson, WE
Parihar, R
Lindemann, MJ
Personeni, N
Dierksheide, J
Meropol, NJ
Baselga, J
Caligiuri, MA
Citation: We. Carson et al., Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells, EUR J IMMUN, 31(10), 2001, pp. 3016-3025
Authors:
Albanell, J
Codony-Servat, J
Rojo, F
Del Campo, JM
Sauleda, S
Anido, J
Raspall, G
Giralt, J
Rosello, J
Nicholson, RI
Mendelsohn, J
Baselga, J
Citation: J. Albanell et al., Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments, CANCER RES, 61(17), 2001, pp. 6500-6510
Authors:
Molina, MA
Codony-Servat, J
Albanell, J
Rojo, F
Arribas, J
Baselga, J
Citation: Ma. Molina et al., Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells, CANCER RES, 61(12), 2001, pp. 4744-4749
Authors:
Borrell-Pages, M
Fernandez-Larrea, J
Borroto, A
Rojo, F
Baselga, J
Arribas, J
Citation: M. Borrell-pages et al., The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein, MOL BIOL CE, 11(12), 2000, pp. 4217-4225
Authors:
Serrano, B
Baselga, J
Bravo, J
Mikes, F
Sese, L
Esteban, I
Pierola, IF
Citation: B. Serrano et al., Chemical imaging of phase-separated polymer blends by fluorescence microscopy, J FLUORESC, 10(2), 2000, pp. 135-139
Authors:
Gonzalez-Benito, J
Aznar, AJ
Lima, J
Bahia, F
Macanita, AL
Baselga, J
Citation: J. Gonzalez-benito et al., Fluorescence-labeled pyrenesulfonamide response for characterizing polymeric interfaces in composite materials, J FLUORESC, 10(2), 2000, pp. 141-146
Authors:
Bellmunt, J
Guillem, V
Paz-Ares, L
Gonzalez-Larriba, JL
Carles, J
Albanell, J
Tabernero, JM
Cortes-Funes, H
Baselga, J
Citation: J. Bellmunt et al., Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer, EUR J CANC, 36, 2000, pp. S17-S25
Authors:
Mendelsohn, J
Baselga, J
Citation: J. Mendelsohn et J. Baselga, The EGF receptor family as targets for cancer therapy, ONCOGENE, 19(56), 2000, pp. 6550-6565
Authors:
Baselga, J
Citation: J. Baselga, Monoclonal antibodies directed at growth factor receptors, ANN ONCOL, 11, 2000, pp. 187-190